MA-PRECISELY
Precisely, the global leader in data integrity, today announced that Etam Group, a major international retailer and leading lingerie brand in France, has implemented its Automate Studio solution across all subsidiaries to support company-wide accounts payable processes. By providing seamless SAP data access to decision-makers in real-time, Automate Studio (formerly Winshuttle Studio) enables Etam’s accounting teams to work autonomously without support from IT personnel, reduce operational costs, and drive greater innovation across the organization.
Business agility is critical in the retail industry, with companies seeking to balance tight margins with the need to innovate and stay competitive. With more pressure than ever to optimize margins through existing operating structures and processes, it comes as no surprise that automation has emerged as a top consideration for retailers in 2024. Retail companies are increasingly seeing the need to simplify and accelerate processes across their major functions to drive business efficiencies, improve customer experience, and stay compliant with an ever-changing regulatory landscape.
“In the retail sector, businesses must stay agile and be able to implement ideas quickly, something which is also incredibly important in accounting,” said Stéphane Delattre, Vice President – Accounting for Europe at Etam Group. “Automate Studio increases our productivity and efficiency, enabling mass data simplification and empowering decision-makers to access trustworthy data in real-time. We call it the ‘miracle product’!”
The Etam Group has an impressive history of driving innovation to optimize infrastructure and provide great customer experience – having invented the concept of just-in-time automatic restocking in 1965. But with presence now in over 1,500 stores located across 57 countries, the retailer needed a solution that would work with its SAP ERP (enterprise resource planning) software and support all the company’s subsidiaries in streamlining their data management.
Automate Studio is the premier Excel-to-SAP solutions platform that enables business users to automate complex SAP business processes and make mass data changes quickly and easily. The platform allows customers to eliminate manual data entries and upload and download SAP data in record time, while simultaneously improving data quality. Automate Studio empowers business teams by reducing their reliance on IT support for automating Excel to SAP processes. Now citizen developers within business teams can create and manage their own solutions faster, while ensuring compliance and security standards are maintained.
“Before we deployed Automate Studio, we manually handled hundreds of invoices a month which could be very time-consuming,” said Delattre. “This practical solution from Precisely has not only increased our internal productivity but has helped us save time. Previously, one invoice took three minutes to create and now Automate Studio facilitates the creation of nearly 600 invoices within 15 minutes. Another example is how drastically it reduced the time needed to add purchasing conditions to orders in SAP – this used to take two days but can now be completed in just two hours.”
“Precisely is committed to helping customers automate their SAP processes to maintain agility, accelerate speed of business, and build the integrity of their data,” said Pat McCarthy, Chief Revenue Officer at Precisely. “As more organizations embark on digital transformation across their core functions, they are realizing the power of process automation, fueled by accurate, consistent, and contextual data to help ensure success.”
Learn more about Precisely Automate Studio.
About Etam Group
One hundred years old, still family-owned and independent, the Etam Group, now a leader in France and internationally, is a key player in innovative and creative lingerie and fashion. With its identity and historical know-how, the Etam Group cultivates this unique relationship with its customers through its brands Etam, Maison 123, Undiz Livy and Ysé, and a strong omnichannel presence based on more than 1500 stores in 57 countries. Learn more at https://etam-groupe.com
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228517820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom